Vol. 1 No. 11 (2021)
Reimbursement Recommendations

Romosozumab (Evenity)

Published November 29, 2021

Key Messages

  • CADTH recommends that Evenity should be reimbursed by public drug plans for the treatment of osteoporosis in postmenopausal women if certain conditions are met.
  • Evenity should only be covered to treat postmenopausal women with a history of osteoporosis-related fracture and who are likely to have such a fracture in the future and who have never received previous medications for osteoporosis.
  • Evenity should only be reimbursed if the cost is reduced and if it is not prescribed concurrently with other osteoporosis medications, except for calcium and/or vitamin D.